GlassScriptPhysician profile
Jared J Herr
NPI 1184959272
$11,630.09
in general payments reported to CMS, 2019-2025
21 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,017 · 2020: $1,165 · 2021: $324 · 2022: $1,889 · 2023: $260 · 2024: $2,679 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119 · Travel and Lodging: $2,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.07 |
| Travel and Lodging | $2,115.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,725.52 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $3,233.67 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $394.82 | 2019-2021 | |
| Abiomed | $260.54 | 2024-2025 | Impella |
| Cathworks, INC. | $152.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $145.40 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $128.88 | 2024 | Optimizer |
| Sanofi-Aventis U.S. LLC | $121.62 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.37 | 2019-2022 | |
| Irhythm Technologies, INC. | $74.94 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Paragonix Technologies, INC. | $43.88 | 2025 | Sherpapak |
| E.R. Squibb & Sons, L.L.C. | $41.56 | 2024 | Camzyos |
| Pfizer INC. | $30.62 | 2025 | |
| One Lambda, INC. | $28.73 | 2024 | |
| Alnylam Pharmaceuticals INC. | $28.30 | 2025 | Onpattro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.93 | 2025 | |
| Janssen Pharmaceuticals, INC | $26.78 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $21.96 | 2019 | |
| Amgen INC. | $21.53 | 2020 | |
| Heartflow, INC. | $21.22 | 2021 | |
| Abbvie INC. | $16.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Herr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.